It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our ...

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales ...

Plus, learn about what to expect in initial interviews and how to time your post-Ph.D. job search for maximum success.

Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in ...

BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...

Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with ...

A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, ...